Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7687488 | ALLECRA THERAPS | 2-substituted methyl penam derivatives |
Dec, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11124526 | ALLECRA THERAPS | Crystalline beta-lactamase inhibitor |
Nov, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Feb 22, 2029 |
Generating Antibiotic Incentives Now(GAIN) | Feb 22, 2034 |
Drugs and Companies using CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM ingredient
NCE-1 date: 22 February, 2033
Market Authorisation Date: 22 February, 2024
Treatment: Use of specified polymorphs of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms;...
Dosage: POWDER;INTRAVENOUS